Biotech Firms Filed For Initial Public Offerings
Retension Pharmaceuticals and TRex Bio moved to list on the Nasdaq exchange this week.
Updated on Sept. 18, 2026 in Biotech
Live Poll
Is now a good time for individual investors to participate in new biotech company IPOs?
Retension Pharmaceuticals and TRex Bio filed paperwork for U.S. initial public offerings on September 18, 2026. The companies plan to list their shares on the Nasdaq exchange under the tickers RTSN and TRXB respectively.
Why it matters
These filings represent a fresh wave of activity in the biotech sector, following a significant $350 million upsized IPO from Electra Therapeutics on the New York stock market. The moves highlight continued capital interest in firms developing specialized medicines for cardiovascular and autoimmune conditions.
Retension Pharmaceuticals, based in Falls Church, Virginia, focuses on hypertension and cardiovascular treatments, while South San Francisco-based TRex Bio targets autoimmune and inflammatory diseases. TRex Bio specifically anticipates releasing clinical trial data for its TRB-061 candidate in mid-2027.
The players
Retension Pharmaceuticals
A Falls Church, Virginia-based biotechnology company that develops pharmaceutical treatments for hypertension and cardiovascular diseases.
TRex Bio
A South San Francisco-based biotechnology firm focused on creating new medicines to address autoimmune and inflammatory diseases.
Electra Therapeutics
A biotech company that recently successfully debuted on the New York stock market after raising $350 million.
Eli Lilly
A major global pharmaceutical company that has announced plans to invest in the upcoming TRex Bio initial public offering.
The details
Retension Pharmaceuticals and TRex Bio filed their S-1 paperwork as the broader biotech market absorbs the recent success of Electra Therapeutics. Eli Lilly has already signaled its intent to participate as an investor in the TRex Bio public offering.
Timeline
Retension Pharmaceuticals and TRex Bio filed IPO paperwork on September 18, 2026.
TRex Bio expects to release TRB-061 clinical trial data in mid-2027.
The Tech Race
These IPOs follow the development milestones of proprietary assets like the TRB-061 clinical trial, which remains a focal point for institutional investors. The public listing environment continues to shift as biotech firms transition from early-stage research into commercialization phases.
The entry of these firms into public markets may provide them with the capital necessary to accelerate the development of treatments for hypertension and autoimmune diseases. Investors and healthcare stakeholders should monitor these tickers for future impacts on drug availability and therapeutic innovation.
The takeaway
The move toward public listings indicates a robust interest in specialized medical research among institutional backers. Investors should closely track upcoming clinical data releases, as these results often determine the long-term success of newly public biotech ventures.
What happens next
TRex Bio is scheduled to report data from its TRB-061 clinical trial in mid-2027.
Further reading
For more on industry shifts, visit the Biotech section.
Live Poll
Is now a good time for individual investors to participate in new biotech company IPOs?
